CVAC

CureVac's Financial Performance: CureVac reported mixed Q4 2024 results with a revenue drop to €14.5 million but achieved an annual revenue of €535.2 million, largely due to a significant licensing agreement with GSK, leading to a return to profitability and a strong cash reserve extending operations into 2028.

Advancements in mRNA Technology: The company is making notable progress in mRNA-based therapies, including FDA-approved trials for lung cancer immunotherapy and ongoing vaccine development for diseases like SARS-CoV-2 and rabies, with analysts maintaining a positive outlook on its growth potential.

U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones dropping approximately 200 points on Friday, while several companies like Argan, Inc. and KULR Technology Group saw significant gains due to strong quarterly earnings reports.

Notable Stock Movements: Argan, Inc. shares surged nearly 30% after exceeding earnings expectations, alongside other companies such as Abacus Global Management and TMC the Metals Company, which also reported better-than-expected results, leading to notable increases in their stock prices.

CureVac Patent Validity Confirmed: The European Patent Office upheld CureVac's patent EP 3 708 668 B1, dismissing BioNTech's opposition and allowing for amendments to clarify its scope. A court ruling on potential infringement is set for July 2025.

Ongoing Legal Disputes: This ruling is part of a larger legal battle involving multiple intellectual property rights between CureVac and BioNTech, with previous disputes including a settlement with Acuitas Therapeutics over COVID-19 vaccine technology.